Regeneron Pharmaceuticals (REGN)
927.89
+109.12 (13.33%)
NASDAQ · Last Trade: Oct 31st, 5:20 PM EDT
News & Press Releases
Regeneron: 3 Key Takeaways for Long-Term Investorsfool.com
An early-stage liver disease therapy cut fat by 70% in just 12 weeks, signaling the genetics engine's potential to fuel growth beyond current blockbusters.
Via The Motley Fool · October 31, 2026
S&P 500 Top Movers: Gainers and Losers in Today's US Sessionchartmill.com
Via Chartmill · October 30, 2026
Regeneron (REGN) stock trades up, here is why
What happened? Shares of biotech company Regeneron (NASDAQ:REGN) jumped 11.5% in the afternoon session after the company reported a 36% increase in third-qua...
Via StockStory · October 30, 2026
S&P 500 Top Movers: Gainers and Losers in Today's Sessionchartmill.com
Via Chartmill · October 30, 2026
Regeneron Pharmaceuticals (NASDAQ:REGN) Q3 2026 Earnings Beat Driven by Dupixent Growthchartmill.com
Via Chartmill · October 30, 2026
What Regeneron Pharmaceuticals (REGN) Said on Its Q3 Earnings Callmarketbeat.com
Regeneron Pharmaceuticals (NASDAQ:REGN) reported third-quarter 2026 revenue growth of 36% year over year to $5.1 billion, while non-GAAP diluted earnings per share rose 70% to $20.07. The company attributed the performance to increased Sanofi collaboration revenue and continued growth from DUPIXENT,
Via MarketBeat · October 30, 2026
Regeneron (REGN) Q3 2026 Earnings Call Transcriptfool.com
Dupixent, EYLEA HD, and Libtayo hit record sales, fueling record earnings growth.
Via The Motley Fool · October 30, 2026
S&P 500 Premarket Gainers and Losers on Oct. 30, 2026chartmill.com
Via Chartmill · October 30, 2026
Regeneron (NASDAQ:REGN) surprises with strong Q3 2026, stock soars
Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q3 2026, with revenue up 36.3% year on year to $5.12 billion....
Via StockStory · October 30, 2026
Regeneron Reports Third Quarter 2026 Financial and Operating Results
TARRYTOWN, N.Y., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced financial results for the third quarter of 2026 and provided a business update.
By Regeneron Pharmaceuticals, Inc. · Via GlobeNewswire · October 30, 2026
What to expect from Regeneron’s (REGN) Q3 earnings
Biotech company Regeneron (NASDAQ:REGN) will be announcing earnings results tomorrow before market hours. Here’s what investors should know. Regeneron beat a...
Via StockStory · October 29, 2026
Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness
Updated agreement expands 2020 procurement agreement with BARDA for Regeneron's first-in-class antibody treatment for Orthoebolavirus zairense, adding value of approximately $270 million
By Regeneron Pharmaceuticals, Inc. · Via GlobeNewswire · October 26, 2026
Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)
Longer-term data reflecting nearly 4 years of follow-up show a further reduction in the risk of death from 14% to 37% for those initially treated with Libtayo, despite an 88% crossover from the placebo arm upon recurrence
By Regeneron Pharmaceuticals, Inc. · Via GlobeNewswire · October 25, 2026
1 safe-and-steady stock with exciting potential and 2 facing headwinds
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on hi...
Via StockStory · October 23, 2026
Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Marketfool.com
Is this company the biggest dark horse in the chronic weight management space?
Via The Motley Fool · October 19, 2026
Forget Eylea: Regeneron's Real Value May Be Hiding in Its Dupixent Profit Sharefool.com
Regeneron's biggest growth driver still has plenty of fuel left in the tank.
Via The Motley Fool · October 17, 2026
Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types
Positive opinion supports reducing Libtayo dosing frequency from every three weeks to every six weeks after first 12 weeks of treatment
By Regeneron Pharmaceuticals, Inc. · Via GlobeNewswire · October 16, 2026
Q2 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the biotechnology industry, including Regeneron (NASDAQ:REGN) and...
Via StockStory · October 14, 2026
Top S&P500 movers in Wednesday's sessionchartmill.com
Via Chartmill · October 14, 2026
Discover which S&P500 stocks are making waves on Monday.chartmill.com
Via Chartmill · October 12, 2026
Pasatru™ (garetosmab-grts) Demonstrates Zero New Heterotopic Ossification (HO) Lesions in Adult Fibrodysplasia Ossificans Progressiva (FOP) Patients During OPTIMA Trial Extension
Pasatru is the first and only FDA-approved treatment demonstrating reductions in both new HO lesions and clinician-assessed flare-ups, per results of a 56-week placebo-controlled trial in adults with FOP
By Regeneron Pharmaceuticals, Inc. · Via GlobeNewswire · October 12, 2026
Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026
Late-breaking Phase 3 C-POST data provide longer-term survival outcomes for adjuvant Libtayo® (cemiplimab) in high-risk cutaneous squamous cell carcinoma (CSCC) after surgery and radiation
By Regeneron Pharmaceuticals, Inc. · Via GlobeNewswire · October 6, 2026
Why Regeneron (REGN) Stock Is Trading Lower Today
What Happened? Shares of biotech company Regeneron (NASDAQ:REGN) fell 4% in the afternoon session after the biotechnology company expanded its immunology all...
Via StockStory · October 1, 2026
Which S&P500 stocks are moving on Thursday?chartmill.com
Via Chartmill · October 1, 2026
Regeneron, Sanofi Expand Alliance in Deal Worth Up to $8 Billionmarketbeat.com
Regeneron Pharmaceuticals (NASDAQ:REGN) and Sanofi said they are expanding their long-running collaboration to develop and commercialize next-generation medicines for type 2 inflammatory diseases, adding four Regeneron-originated antibody programs and establishing a new equal-sharing economic framew
Via MarketBeat · October 1, 2026